MoneyWorks4Me

Biocon gets India marketing rights for Roche’s cancer drug clone: Report

25 Nov 2013 Evaluate

Biocon, Asia’s leading biotechnology enterprise, has reportedly received India marketing rights for Roche’s cancer drug clone. The cancer drug has market of around $6 billion globally. Moreover, the company is likely to market Roche’s cancer drug clone by end of FY14.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..